Silver nanoparticles against HIV-1

1 Comment so far

>> Thursday, February 18, 2010

World Aids Day, December 1
Many biological applications of nanoparticles are being explored including biosensors, labels for cells and biomolecules and cancer therapeutics. In 2005, silver nanoparticles were studied for their role against HIV-1 by researcher from the University of Texas, USA.
In this study, three different silver nanoparticles, carbon coated, poly (N-vinyl-2-pyrrolidone) (PVP) coated and bovine serum albumin (BSA) conjugated, were used and the average size distributions for each preparation were 16.19±8.68 nm, 6.53±2.41 nm and 3.12±2.00 nm respectively. High angle annular dark field (HAADF) scanning transmission electron microscopy was used to study the interaction of silver nanoparticles with HIV-1.

Photo degradation of rofecoxib, a COX-2 inhibitor

4 Comments so far

>> Tuesday, February 09, 2010

Researcher from Monash University, Australia has reported a photocyclization product of rofecoxib. Discovery happened unexpectedly while trying to find new polymorph of rofecoxib. The compound was analyzed and characterized as 6-methylsulphonylphenanthro-[9, 10-C] furan-1 (3H)-one.

“Rofecoxib, a well known COX-2 inhibitor, has been used as anti-inflammatory agent. But due to increased cardiovascular risks, it has been withdrawn from the market.”
Author obtained the degraded product by recrystallization and co-precipitation method. In recrystallization, 10 mg of rofecoxib was dissolved in 2 mL of ethyl acetate and stirred at 65 °C for 15 min. and in case of co-precipitation, 10 mg of rofecoxib was stirred in 2 mL 10% hydroxypropyl-β-cylclodextrin solution at 60 °C for 72 h. Solutions exposed to room light intensity were filtered and left to evaporate at room temperature for one month to get the crystals.

Promising activity of Sorafenib as a therapeutic option for Osteosarcoma

5 Comments so far

>> Wednesday, February 03, 2010

Sorafenib, drug approved for the treatment of kidney, liver and thyroid carcinoma, has been studied for its effect on Osteosarcoma (OS) by researcher from University of Torino medical School, A.O, Torino, Italy. It is an orally active biarylureic multi-Kinase inhibitor which can block the ERK 1/2 pathway by targeting Raf-kinases, such as RAF-1 and B-RAF. It is marketed as Nexavar by Bayer pharmaceutical company.

Authors found that Phospho-ERK 1/2, MCL-1, and phospho-Ezrin/Radixin/Moesin (P-ERM) pathways were highly activated in OS cell lines as analyzed by immunohistochemistry. Sorafenib inhibited OS cell line proliferation, induced apoptosis and downregulated P-ERK 1/2, MCL-1 and P-ERM in a dose-dependent manner.

  © Medchemblog, 2009-present Webnolia by 2009

Back to TOP